MEA Travel Vaccine Market - Industry Trends and Forecast to 2034
Middle East and Africa travel vaccine market is expected to reach USD 1,210,595.40 thousand by 2032 from USD 646,979.92 thousand in 2023, growing at a substantial CAGR of 7.4% in the forecast period of 2024 to 2032.
Market Segmentation:Middle East and Africa travel vaccines market, By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric and Geriatric), Age Group (20-50 Years, Less than 20 Years and Above 50 Years), Distribution Channel (B2B and B2C), Countries (Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa) , Industry Trends and Forecast to 2032
Some of the major factors contributing to the growth of the Middle East and Africa travel vaccines market are:Driver
• Rising incidence of infectious diseases
Restraint
• High cost of travel vaccines
Opportunity
• Advancements in vaccine technology
Market PlayersSome major companies dealing in the Middle East and Africa travel vaccines market are:
• GSK plc.
• Pfizer Inc.
• Abbott
• CSL
• AstraZeneca
• Sanofi
• Merck & Co., Inc.
• Johnson & Johnson Services Inc.
• Dynavax Technologies.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.